Cesar Hernandez-Arroyo, MD
Nephrology · Trujillo Alto, PRNPI 1528473733
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,794 of the $13,083 with a category attached, or 74.9%. It is spread thinly across 24 manufacturers, the largest accounting for just 19.2%. Among nephrology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $80.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$3K
- Medtronic$2K
- AstraZeneca$2K
- Bayer$791
- GSK$642
- Travere Therapeutics, Inc.$611
- plus $4K from 18 others
What the payments were for
- Travel & lodging$3,16124%
- Food & beverage$9,79475%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 16 | $2,518 |
| Medtronic | 16 | $2,465 |
| AstraZeneca | 33 | $1,633 |
| Bayer | 8 | $791 |
| GSK | 13 | $642 |
| Travere Therapeutics, Inc. | 5 | $611 |
| Mallinckrodt Hospital Products Inc. | 7 | $526 |
| Amgen(2 entities) | 5 | $514 |
| Vifor Pharma, Inc. | 7 | $488 |
| ANI Pharmaceuticals, Inc. | 16 | $464 |
| Novartis | 4 | $401 |
| Calliditas Therapeutics US Inc. | 8 | $397 |
| Otsuka America Pharmaceutical, Inc. | 3 | $282 |
| Novo Nordisk | 3 | $242 |
| Boston Scientific | 2 | $149 |
| Bayer Puerto Rico Inc. | 6 | $146 |
| Scpharmaceuticals Inc. | 2 | $146 |
| Johnson & Johnson | 2 | $139 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Veloxis Pharmaceuticals, Inc. | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $75 |
| Alnylam Pharmaceuticals Inc. | 1 | $75 |
| Pfizer | 1 | $73 |
| Boehringer Ingelheim | 2 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,083 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xigduo XrDapaglifloz Propaned/Metformin | 79 | $66,745 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 67 | $59,188 |
| FarxigaDapagliflozin Propanediol | 47 | $37,798 |
| Jentadueto XrLinagliptin/Metformin Hcl | 34 | $24,736 |
| GlyxambiEmpagliflozin/Linagliptin | 25 | $23,865 |
| JardianceEmpagliflozin | 12 | $10,957 |
| Candesartan Cilexetil | 70 | $9,078 |
| Rosuvastatin Calcium | 278 | $4,782 |
| Irbesartan | 91 | $4,064 |
| SynthroidLevothyroxine Sodium | 27 | $3,622 |
| HumalogInsulin Lispro | 17 | $2,325 |
| Insulin Glargine-Yfgn | 24 | $2,202 |
| Losartan Potassium | 130 | $1,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,655 |
| Metoprolol Succinate | 86 | $1,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jentadueto Xr, Glyxambi, Jardiance | $55 | $118,746138 claims |
| AstraZenecaFarxiga | $1,633 | $37,79847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Trujillo Alto
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
- Ricardo Alicea-GuevaraToa Baja$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.